Delivering Therapy for Hepatitis C Virus Infection to Incarcerated HIV-Seropositive Patients

The increase in morbidity and mortality due to end-stage liver disease has fueled recent guidelines that recommend consideration of treatment for hepatitis C in human immunodeficiency virus (HIV)–infected patients. Unfortunately, studies indicate that few patients coinfected with HIV and hepatitis C...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2005-07, Vol.41 (Supplement-1), p.S56-S62
Main Authors: McGovern, Barbara, Fiore, Joseph, Wurcel, Alysse, Taglienti, Paul, Bradley, Meg, Galvin, Susan, Libone, George, Ramsey, Jean, Molinaro-Gudas, Valerie, Drewniak, Stephen, Amick, Carol, Andalkar, Anjali, Scheft, Harriet, Bica, Ioana
Format: Article
Language:English
Subjects:
AIDS
Chronic hepatitis
Clinical outcomes
Demography
Disease management
Drug Interactions
Female
Genotype
Genotypes
Hepacivirus
Hepacivirus - genetics
Hepatitis
Hepatitis C
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C - epidemiology
Hepatitis C - pathology
Hepatitis C virus
HIV
HIV Infections - complications
Human immunodeficiency virus
Humans
Infections
Infectious diseases
Interferon-alpha - administration & dosage
Liver
Liver - pathology
Male
Prisoners
Ribavirin - administration & dosage
Substance-Related Disorders - complications
Substance-Related Disorders - therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The increase in morbidity and mortality due to end-stage liver disease has fueled recent guidelines that recommend consideration of treatment for hepatitis C in human immunodeficiency virus (HIV)–infected patients. Unfortunately, studies indicate that few patients coinfected with HIV and hepatitis C virus (HCV) are treated for their underlying hepatitis because of ongoing substance abuse, depression, chaotic lifestyles, homelessness, and perceived nonadherence. The structured environment of the prison system enables clinicians to provide complicated therapies for HCV to HIV-infected patients in combination with substance abuse programs. Furthermore, adherence to and adverse effects of therapy can be closely monitored. Offering treatment for HCV infection during incarceration to HIV-seropositive persons is highly efficient and targets underserved minority patients who have limited access to care in the community.
ISSN:1058-4838
1537-6591
DOI:10.1086/429497